Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …

In the era of targeted therapy based on genomic alterations, the treatment strategy for
metastatic colorectal cancer (mCRC) has been changing. Before systemic treatment …

Background In a previous phase 3 trial, treatment with trifluridine–tipiracil (FTD–TPI)
prolonged overall survival among patients with metastatic colorectal cancer. Preliminary …

Colorectal cancer (CRC) is the third most common cancer worldwide, with 1.1 million new
cases per year, and is the second leading cause of cancer death. 1 CRC occurs more …

Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly develo** a
strong evidence base for use in patients with cancer. The European Society for Medical …

Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the
treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of …

Background Immune checkpoint inhibitors have not shown clinical benefit to patients with
metastatic colorectal cancer who had proficient mismatch repair (pMMR) or microsatellite …

Immunotherapy has revolutionized colon cancer treatment. Immune checkpoint inhibitors
(ICIs) have shown clinical benefits for colon cancer patients, especially those with high …

Colorectal cancer (CRC) is one of the most prevalent and deadly cancers worldwide.
Despite recent improvements in treatment and prevention, most of the current therapeutic …

Significant progress has been achieved in the treatment of metastatic colorectal cancer
(mCRC) patients during the last 20 years. There are currently numerous treatments …